🧫
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease
experiment
Created: 2026-04-02T17:01:41
By: crosslink-v2
Quality:
67%
✓ SciDEX
ID: experiment-exp-wiki-experiments-senolyti
🧫 Experiment Protocol
Clinical
Metadata
| experiment_type | clinical |
| source | {'type': 'manual', 'source_name': 'wiki', 'extraction_date': '2026-04-16T01:00:16.907032Z', 'extracted_by': 'backfill_v1'} |
| entities | {'genes': ['SASP'], 'diseases': ["Alzheimer's Disease"]} |
| model_system | human |
| summary | # Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease ## Background and Rationale This Phase IIa clinical trial evaluates the therapeutic potential of senolytic therapy using dasatini |
| replication_status | single_study |
| methodology_notes | **Phase 1: Screening and Baseline Assessment (Weeks -4 to 0)** • Screen 200 potential participants aged 60-85 with mild cognitive impairment or early AD (CDR 0.5-1.0) • Confirm amyloid positivity via |
| primary_outcome | Change from baseline in cerebrospinal fluid SASP inflammatory markers (IL-6, TNF-α, IL-1β composite score) at 12 months in patients receiving D+Q versus placebo. |
| extraction_metadata | {'extraction_confidence': 0.4, 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'backfill_at': '2026-04-16T01:00:16.907038'} |
🌍 Provenance Graph
9 nodes, 30 edges
derives from (16)
...and 11 more
Linked Artifacts (1089)